Introduction {#cwz019s1}
============

Antithrombin (ATIII) and heparin cofactor II (HCII) are the serpins responsible for in vivo inhibition of thrombin ([@cwz019C21]). Upon interaction with heparin or dermatan sulfate (DS), the rate of inhibition is increased 1000-fold ([@cwz019C8]; [@cwz019C20]). Whereas heparin affects thrombin inhibition via both ATIII and HCII, DS acts solely through HCII in the vessel walls after endothelial damage (Figure [2](#cwz019F2){ref-type="fig"}A) ([@cwz019C7]). DS is composed of alternating *N*-acetyl-[d]{.smallcaps}-galactosamine (GalNAc) and [l]{.smallcaps}-iduronic acid (IdoA) residues. To form IdoA in DS, two chain-modifying enzymes are required; DS epimerase 1 (DS-epi1) and dermatan 4-*O*-sulfotransferase 1 (D4ST1) ([@cwz019C3]; [@cwz019C13]). DS-epi1 is responsible for the inversion of stereochemistry of carbon 5 in GlcA, to form IdoA, while D4ST1 transfers a sulfate group from 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to C4 of a GalNAc adjacent to IdoA ([@cwz019C3]). In addition, uronyl 2-*O*-sulfotransferase (UST) and *N*-acetylgalactosamine 4-sulfate 6-*O*-sulfotransferase (GalNAc4S-6ST) transfer sulfate groups to C2 of IdoA and C6 of GalNAc4S, respectively, generating di- and trisulfated structures. DS (MF 701) has been used as an anticoagulant in hemodialysis, disseminated intravascular coagulation and hip fractures ([@cwz019C2]). Furthermore, danaparoid, a combination of heparan sulfate and DS, is used in heparin-induced thrombocytopenia ([@cwz019C1]). These glycosaminoglycan-derived anticoagulants are far from ideal drugs due to their (i) animal origin, (ii) narrow therapeutic window and (iii) inherent structural dishomogeneity. The latter problems were exposed in the 2008 heparin crisis where oversulfated chondroitin sulfate illegally added to heparin caused fatal anaphylactic reactions ([@cwz019C4]). To address some of these problems, we initiated a study to produce structurally well-defined recombinant DS (recDS) with anticoagulant activity from the microbial K4 polysaccharide, using the recombinant enzymes DS-epi1, D4ST1, UST and GalNAc4S-6ST.

Results and discussion {#cwz019s2}
======================

Structurally well-defined recombinant dermatan sulfate can be produced from a bacterial polysaccharide substrate {#cwz019s3}
----------------------------------------------------------------------------------------------------------------

As previously shown, incubation of chondroitin with DS-epi1 alone results in short stretches of IdoA-containing sequences ([@cwz019C23]). In order to produce long IdoA-blocks ([@cwz019C22]), DS-epi1 and D4ST1 were co-incubated with chondroitin and PAPS for 24 h (Figure [1](#cwz019F1){ref-type="fig"}A and B) to give a product (recDS-4) containing 96% UA-GalNAc-4S, determined by disaccharide analysis after chondroitinase ABC (Figure [1](#cwz019F1){ref-type="fig"}C). The presence of IdoA and GalNAc-4S was shown by disaccharide analysis after chondroitinase B (data not shown) and confirmed by NMR spectroscopy (Figure [1](#cwz019F1){ref-type="fig"}D). Further characterization by SEC-MALS showed a weight average molecular weight (*M*~w~) of 35.5 kDa with a dispersity of 1.14 (Figure [1](#cwz019F1){ref-type="fig"}E). Based on the sulfation degree and the size of the polymers it can be concluded that the 4% of non-sulfated disaccharide structures in recDS-4 are most likely positioned on the reducing and non-reducing ends of the polymer, in agreement with the substrate specificity of both DS-epi1 and D4ST1 ([@cwz019C3]; [@cwz019C15]; [@cwz019C23]). Depending on the potential future applications of the recDS, we could also show that it is also possible to tune the degree of 4-*O*-sulfated residues by varying the enzymatic incubation time (Figure [1](#cwz019F1){ref-type="fig"}B). In contrast to the heterogeneity of commercial 4-*O*-sulfated DS preparations isolated from animal sources, the unique recDS-4 preparation is homogenously composed of IdoA-GalNAc-4S along the polymer and can be used to evaluate the biological properties and functions of 4-*O*-sulfated DS.

![Synthesis and analysis of recombinant anticoagulant DS. (**A**) Synthesis scheme for recDS production. (**B**) Kinetics of recDS-4 formation. By varying the enzymatic incubation time, the degree of modification can be tuned. Two repeats were performed, both in triplicates, giving similar results. Representative data from one repeat is shown as the mean ± one standard deviation. (**C**) Disaccharide analysis of the recDS products after chondroitinase ABC digestion. (**D**) ^1^H and ^13^C NMR shifts of the recDS-4 product. (**E**) Size analysis of the recDS-4 product by multi-detection size exclusion chromatography, showing the refractive index signal in blue and the absolute molecular weight around the peak apex in red.](cwz019f01){#cwz019F1}

The recDS-4 product was further sulfated using UST to form a 71% 2,4-*O*-sulfated recDS-2,4 (Figure [1](#cwz019F1){ref-type="fig"}C). Interestingly, initial experiments showed that 2-*O*-sulfation of unsulfated chondroitin or dermatan was slow and few sulfate groups were added. We propose that UST preferably transfers sulfate groups to 4-*O*-sulfated DS, in agreement with earlier observations ([@cwz019C9]). Finally, disulfated 4,6-*O*- (86%) or trisulfated 2,4,6-*O*- (54%) recDS could be obtained by incubation of recDS-4 or recDS-2,4, respectively, with GalNAc4S-6ST (Figure [1](#cwz019F1){ref-type="fig"}C). These results extend the substrate specificity of GalNAc4S-6ST to 2,4-*O*-sulfated DS, in addition to the previously known mono-4-*O*-sulfated substrates ([@cwz019C17]).

A recombinant 2,4-*O*-sulfated DS is a potent activator of HCII-dependent inhibition of thrombin {#cwz019s4}
------------------------------------------------------------------------------------------------

To investigate the functionality of our recDS preparations, an assay for the HCII-dependent inactivation of thrombin was set up. The 4-*O*-sulfated recDS showed no activity. However, the 4,6-*O*-sulfated recDS with 86% IdoA-GalNAc-4,6 sulfate exhibited a HCII-dependent inactivation of thrombin with similar potency as heparin, i.e., IC~50~ values of 479 ± 95 ng/mL and 348 ± 25 ng/mL, respectively (Figure [2](#cwz019F2){ref-type="fig"}B). A DS preparation with 9% 4,6-*O*-sulfated structures has previously been shown to weakly inhibit thrombin via HCII, suggesting that a significantly higher proportion of disulfated structures is necessary for efficient inhibition ([@cwz019C5]). Most importantly, we found that a preparation with 71% of IdoA-2S-GalNAc-4S had an IC~50~ value of 19 ± 4 ng/mL, i.e., 15-20 times better inhibition compared to heparin ([@cwz019C14]). To our knowledge, this is the most potent native polysaccharide activator of HCII to date. Trisulfated recDS had an IC~50~ value of 19 ± 6 ng/mL, suggesting that additional sulfation does not improve activation.

![Evaluation of the anticoagulant properties of recombinant DS. (**A**) Simplified overview of the common pathway of thrombin generation. Heparin inhibits coagulation via both ATIII and HCII, whereas DS has a singular anticoagulant activity, via HCII. (**B**) Inhibition of thrombin by HCII in the presence of heparin (●), recDS-4 (✳), recDS-4,6 (♦), recDS-2,4 (▲), and recDS-2,4,6 (■). Two repeats were performed, both in triplicates, giving similar results. Representative data from one repeat is shown as the mean ± one standard deviation. (**C**) Activated partial thromboplastin time of heparin (●) and recDS-2,4 (▲) at various concentrations. Replicate data points are shown staggered for clarity. Results are from one experiment performed in triplicates using the SWEDAC accredited method (NPU01682) at the Skåne University Hospital.](cwz019f02){#cwz019F2}

In order to verify these results in in vivo-like settings, we analyzed the ability of the 2,4-*O*-sulfated recDS to prolong the activated partial thromboplastin time (aPTT) (Figure [2](#cwz019F2){ref-type="fig"}C). The concentration required to double the aPTT was 13.0 ± 0.8 μg/mL for 2,4-*O*-sulfated recDS, compared to 3.5 ± 0.2 μg/mL for heparin. Even though the 2,4-*O*-sulfated recDS only acts via HCII, and not ATIII (Figure [2](#cwz019F2){ref-type="fig"}A), the activity is four times lower than that of heparin when comparing mass concentrations and only one point five times lower when comparing molar concentrations (\~16 kDa versus \~40 kDa for heparin and recDS-2,4, respectively).

While chemoenzymatic synthesis is highly developed for heparin/heparan sulfate, the production of recombinant dermatan sulfate has so far gained less attraction ([@cwz019C25]; [@cwz019C26]). In this article we report that functional DS, of non-eukaryotic origin, with well-defined chemical structures can be produced, enabling production of DS with different amounts of IdoA, 2-*O*-, 4-*O*-, and 6-*O*-sulfate.

The control of blood coagulation is of outermost importance, and we show that recombinant DS inhibits thrombin via heparin cofactor II, approximately 20 times better than heparin, enabling manipulation of vascular and extravascular coagulation. Based on previously reported functions of mammalian DS, our method can potentially be extended to preparation of structures that are of importance for binding and activation of cytokines, control of collagen matrix structure, inflammation and metastasis involving P-selectin mediated extravasation and cancer cell migration ([@cwz019C12]; [@cwz019C11]; [@cwz019C19]; [@cwz019C16]; [@cwz019C24]).

Materials and methods {#cwz019s5}
=====================

Materials {#cwz019s6}
---------

PAPS and chondroitin was prepared as described previously ([@cwz019C6]; [@cwz019C27]). Unfractionated heparin sodium salt with a weight average molecular weight (*M*~w~) of 15.5 kDa and a dispersity of 1.28 (determined by multi-detection SEC, as below) was from porcine intestinal mucosa (Sigma-Aldrich H3393, Grade I-A, 179 USP units/mg).

Cloning and expression of DS-epi1, D4ST1, UST and GalNAc4S-6ST {#cwz019s7}
--------------------------------------------------------------

DS-epi1 and D4ST1 were cloned and expressed as previously described ([@cwz019C23], [@cwz019C22]).

The part of the open reading frame of the human uronyl 2-*O*-sulfotransferase (UST) gene *UST* (sequence harmonized, Genewiz, USA) corresponding to the lumenal amino acids 71 to 406 was subcloned together with a C-terminal 8xHIS tag into the NheI and NotI sites of a pCEP-Pu/BM40 ([@cwz019C10]) (modified version of pCEP4 from Invitrogen) expression vector using the following primers (Sigma-Aldrich):

Forward (NheI restriction site in bold letters)

Amino acid 71:5′-GCATCT**GCTAGC**CCCCCCTAGATTCCTGCTCG-3′

Reverse (NotI restriction site in bold letters)

Amino acid 406: 5′-GCATCT**GCGGCCGC**TCAATGGTGATGGTGATGATGGTGGTGTCTTTTGTAGATGTCCTCGAGC-3′.

The part of the open reading frame of the human *N*-acetylgalactosamine 4-sulfate 6-*O*-sulfotransferase (GalNAc4S-6ST) gene *CHST15* (sequence harmonized, Genewiz, USA) corresponding to the lumenal amino acids 102 to 561 was subcloned together with a C-terminal 8xHIS tag into the NheI and NotI sites of pCEP-Pu/BM40 using the following primers (Sigma-Aldrich):

Forward (NheI restriction site in bold letters)

Amino acid 102: 5′-GCATCT**GCTAGC**CCATCAGGAGCTCCTGATTTCC -3′

Reverse (NotI restriction site in bold letters)

Amino acid 561: 5′-GCATCT**GCGGCCGC**TCAATGGTGATGGTGATGATGGTGGTGGGTGGTCTTCCAAGCGAAAG-3′

Transfection, expression and purification was performed as previously described ([@cwz019C23]).

Preparation of recombinant dermatan sulfate {#cwz019s8}
-------------------------------------------

**recDS-4:** DS-epi1 (242 μg, 2.7 nmol) was mixed with D4ST1 (266 μg, 5.9 nmol), PAPS (33 μmol), bovine serum albumin (BSA) (120 mg) and chondroitin (308 μg, 0.81 μmol HexA) in final 100 mL MES buffer (20 mM, pH 6.5) supplemented with MnCl~2~ (10 mM). The sample was incubated at 37°C for 24 h under agitation. The polysaccharide product was purified by anion exchange chromatography on a 1 mL HiTrap DEAE FF column (GE Healthcare) equilibrated with 50 mM NaOAc, pH 5.0 at 1 mL/min, using an ÄKTA Start (GE Healthcare). The DEAE column was then washed with 5 mL 50 mM NaOAc, pH 5.0 and finally eluted with a 30 mL gradient, going from 50 mM NaOAc, pH 5.0, to 50 mM NaOAc, pH 5.0, +2 M NaCl. Fractions of interest were desalted with milli-Q water on a 4 mL Amicon Ultra 10 kDa column (Millipore).

**recDS-2,4:** UST (1700 μg, 32.1 nmol) was mixed together with PAPS (17.5 μmol), BSA (50 mg) and 4-*O*-sulfated recombinant DS (115 μg, 0.25 μmol HexA) in final 50 ml MES buffer (20 mM, pH 6.5) supplemented with MnCl~2~ (10 mM). The sample was incubated at 37°C for 48 h under agitation. The polysaccharide product was purified as above.

**recDS-4,6:** GalNAc4S-6ST (12.5 μg, 0.2 nmol) was mixed together with PAPS (17.5 μmol), BSA (50 mg) and 4-*O*-sulfated recombinant DS (115 μg, 0.25 μmol HexA) in final 50 mL MES buffer (20 mM, pH 6.5) supplemented with MnCl~2~ (10 mM). The sample was incubated at 37°C for 48 h under agitation. The polysaccharide product was purified as above.

**recDS-2,4,6:** UST (120 μg, 2.3 nmol) was mixed together with PAPS (50 μL, 1.75 μmol), BSA (5 mg) and 4,6-*O*-sulfated recombinant DS (11 μg, 20 nmol HexA) in final 5 mL MES buffer (20 mM, pH 6.5) supplemented with MnCl~2~ (10 mM). The sample was incubated at 37°C for 24 h in an Eppendorf ThermoMixer C operated with vortexing at 600 rpm. The polysaccharide product was purified as above.

Disaccharide analysis {#cwz019s9}
---------------------

Disaccharide analysis was essentially performed as described previously ([@cwz019C18]). In short, samples were buffer exchanged into an ammonium acetate buffer (50 mM, pH 7.5) and to each sample, in approximately 30 μL, chondroitinase ABC (10 mIU, Sigma-Aldrich) was added to depolymerize the polysaccharide products to Δ^4,5^-unsaturated uronic acid containing disaccharides. Depolymerization was achieved by incubation at 37°C for 4 h, after which the samples were boiled, centrifuged at 20,000 × *g* for 10 min and the supernatant was dried in a centrifugal concentrator and saved for future analysis. Pre-column, 2-aminoacridone-labeled DS disaccharides were analyzed on a Thermo Scientific UltiMate 3000 Quaternary Analytical system equipped with an FLD-3400RS fluorescence detector. For recDS-4, the polysaccharides were also degraded using chondroitinase B (2 mIU, R&D Systems) in 30 μL ammonium acetate buffer (50 mM, pH 7.5) overnight at 37°C. Disaccharide standards were from Iduron (Manchester, UK).

Multi-detection SEC {#cwz019s10}
-------------------

SEC was performed using a Malvern Panalytical OMNISEC system (Malvern, UK) consisting of Refractive Index (RI), Right Angle and Low Angle light scattering (RALS/LALS) and differential viscometer. All data was collected and processed using OMNISEC v10. For chromatographic separation, a Malvern Panalytical PLS3030 column (300 Å, 3 μM, 7.8 × 300 mm) was used with PBS buffer. For analysis of the polysaccharides a dn/dc of 0.12 ml/g was used as it was assumed that all samples had a composition like that of heparin.

NMR analysis {#cwz019s11}
------------

Experiments were performed at 298 K on a Bruker Avance III HD 800 MHz equipped with a TXO cryo probe and referenced to HDO at 4.70 ppm, with the following settings: **1 H 1D.** Pulse sequence zg30, 256 scans, acquisition time 2.05 s. Alternatively, pulse sequence 1D with excitation sculpting with perfect echo based on zgespe, 512 scans, acquisition time 2.05 s. **13 C 1D.** Pulse sequence zgzrse, 32768 scans, acquisition time 1.024 s. **1H-13C HSQC.** Pulse sequence hsqcedetgpsisp2.4, 64 scans, acquisition time 80 ms, TD 256 × 2048 (f1 × f2), dummy scans 32, offset 13 C 80.0 ppm. Spectra were analyzed using TopSpin 3.5pl7.

Inhibition of thrombin by heparin cofactor II and DS {#cwz019s12}
----------------------------------------------------

Glycosaminoglycans (0--50 μg/mL, quantified by disaccharide analysis) were mixed with human thrombin (1 nM, R&D Systems) in 15 μL buffer composed of Tris-HCl (50 mM, pH 7.5), sodium chloride (150 mM), calcium chloride (10 mM) and Brij-35 (0.05% (v/v)). The mixture was incubated for 5 min at 22°C before addition of HCII (15 μL, 30 nM, R&D Systems). After 15 min at 22°C, Chromozym TH (100 μL, 0.2 mM, Roche) was added and the absorbance measured at 405 nm for 600 s at 20 s intervals. All the above concentrations in parenthesis are final. All experiments were performed in triplicates.

aPTT analysis {#cwz019s13}
-------------

aPTT was measured in triplicates by a SWEDAC accredited (ISO 15189) medical laboratory at the Skåne University Hospital on a CS-5100 automated analyzer (Siemens, Marburg, Germany) using the Actin FSL reagent (Siemens). The reference interval was 26-33 s with a coefficient of variation of \<4%.

Statistical analysis {#cwz019s14}
--------------------

Data are expressed as mean values ± one standard deviation of experiments performed in triplicates, calculated using GraphPad Prism version 8.0.0.
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